PMID- 37718403
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230922
IS  - 1008-8830 (Print)
IS  - 2096-9228 (Electronic)
IS  - 1008-8830 (Linking)
VI  - 25
IP  - 9
DP  - 2023 Sept 15
TI  - [Clinical efficacy of omalizumab for treatment of moderate or severe allergic 
      asthma in children with serum immunoglobulin E levels >1 500 IU/mL: a prospective 
      study].
PG  - 959-965
LID - 1008-8830(2023)09-0959-07 [pii]
LID - 10.7499/j.issn.1008-8830.2303102 [doi]
AB  - OBJECTIVES: To evaluate the clinical efficacy of omalizumab in the treatment of 
      moderate or severe allergic asthma in children with serum total immunoglobulin E 
      (IgE) levels >1 500 IU/mL. METHODS: A total of 95 children with moderate or 
      severe allergic asthma, who were treated at the Department of Respiratory 
      Medicine in Anhui Provincial Children's Hospital from December 2020 to May 2022, 
      were enrolled. Based on their serum total IgE levels and whether they received 
      omalizumab treatment, they were divided into a control group (IgE >1 500 IU/mL, 
      no omalizumab treatment), a normal treatment group (IgE levels between 30 and 1 
      500 IU/mL, omalizumab treatment), and an ultra-high IgE treatment group (IgE >1 
      500 IU/mL, omalizumab treatment). The differences in clinical characteristics, 
      Childhood Asthma Control Test (C-ACT) scores before and after treatment, the 
      proportion of acute attacks, IgE levels, pulmonary function indicators, and 
      fractional exhaled nitric oxide (FeNO) concentrations were analyzed among the 
      three groups. RESULTS: At the 8th week of treatment, the normal treatment group 
      and the ultra-high IgE treatment group had higher C-ACT scores, forced expiratory 
      volume in first second (FEV(1)) as a percentage of predicted value (FEV(1)%pred), 
      FEV(1)/forced vital capacity (FVC) ratio (FEV(1)/FVC), and peak expiratory flow 
      (PEF) as a percentage of predicted value (PEF%pred), as well as a lower 
      proportion of acute attacks and FeNO concentration compared to the control group 
      (P<0.05). There were no statistically significant differences in the comparison 
      of various indicators between the ultra-high IgE treatment group and the normal 
      treatment group (P>0.05). At the 16th week of treatment, the normal treatment 
      group and the ultra-high IgE treatment group had higher C-ACT scores and 
      pulmonary function indicators including FEV(1)%pred, FEV(1)/FVC, PEF%pred, and 
      forced expiratory flow at 25% vital capacity (FEF(25)) as a percentage of 
      predicted value (FEF(25)%pred) compared to the control group (P<0.05). The 
      proportion of acute attacks and FeNO concentration in the ultra-high IgE 
      treatment group were lower than those in the control group (P<0.05). There were 
      no statistically significant differences in the comparison of various indicators 
      between the ultra-high IgE treatment group and the normal treatment group 
      (P>0.05). CONCLUSIONS: Omalizumab therapy has a certain clinical efficacy in 
      children with moderate or severe allergic asthma and serum total IgE levels >1 
      500 IU/mL, with no significant difference in efficacy compared to children with 
      serum total IgE levels between 30 and 1 500 IU/mL.
FAU - Luo, Ming-Xin
AU  - Luo MX
AD  - Department of Respiratory Medicine, Anhui Provincial Children's Hospital, Hefei 
      230000, China.
FAU - Hua, Shan
AU  - Hua S
AD  - Department of Respiratory Medicine, Anhui Provincial Children's Hospital, Hefei 
      230000, China.
FAU - Wei, Wen
AU  - Wei W
AD  - Department of Respiratory Medicine, Anhui Provincial Children's Hospital, Hefei 
      230000, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
TT  - 奥马珠单抗治疗血清总IgE>1 500 IU/mL的中重度过敏性哮喘儿童的前瞻性研究.
PL  - China
TA  - Zhongguo Dang Dai Er Ke Za Zhi
JT  - Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
JID - 100909956
SB  - IM
PMC - PMC10511235
OTO - NOTNLM
OT  - Allergic asthma
OT  - Child
OT  - Immunoglobulin E
OT  - Omalizumab
COIS- 所有作者声明无利益冲突。
EDAT- 2023/09/18 00:41
MHDA- 2023/09/18 00:42
PMCR- 2023/09/15
CRDT- 2023/09/17 23:13
PHST- 2023/09/18 00:42 [medline]
PHST- 2023/09/18 00:41 [pubmed]
PHST- 2023/09/17 23:13 [entrez]
PHST- 2023/09/15 00:00 [pmc-release]
AID - 1008-8830(2023)09-0959-07 [pii]
AID - 10.7499/j.issn.1008-8830.2303102 [doi]
PST - ppublish
SO  - Zhongguo Dang Dai Er Ke Za Zhi. 2023 Sept 15;25(9):959-965. doi: 
      10.7499/j.issn.1008-8830.2303102.